However, these same ligands acted as partial inverse agonists on CB2 expressed in CHO cells (Fig. We quantified the relative content of lipids and cholesterol in several preparations...
Then, the role of cannabinoid receptors 1 and 2 (CB1 and CB2) on interleukin expression and release was investigated in middle stage AEC using selective agonists and antagonists. End...
3A), and had no effect on the other terpenes (Fig. 3A) while having no effect on the other terpenes (Fig. Overall, our mechanistic studies suggest that the terpenes tested generally ...
Autism. Autism. Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. Autism. Autism.
Like most modern molecular biology and natural product chemistry, understanding cannabinoid pharmacology centers around molecular interactions, in this case, between the cannabinoids...
Treatments were: (1) oral placebo, (2) whole-plant cannabis extract containing CBD and THC at a 20:1 ratio, and (3) pure CBD and pure THC at the same ratio and concentration. Impact ...
The synapses between Aδ, Aβ, and C fibers and spinal cord neurons are excitatory, having glutamate as neurotransmitter (West et al., 2015; Alles and Smith, 2018). In addition to the ...
Two recent publications examining selected cannabinoid concentrations in human over-the-counter products showed a tremendous disparity between labeling claims and analysis of the pro...
Upon ligand binding, CB1 receptors can also induce PI3K/Akt activation in many cell types including glial cells where it promotes cell survival (Galve-Roperh et al., 2002; Gomez et a...
Cannabinoid Receptors 2.1. Interestingly, under pathological conditions, various peripheral cell types have also been shown to express detectable levels of the CB2R. Signaling 2.4....
In this study, using data from The Cancer Genome Atlas (TCGA)’s melanoma cohort, human melanoma tissues and murine models, as well as single-cell RNA sequencing, we uncover a critica...
Cell. Cell. Cell. Genes Cells 2015, 20, 324–339. Cell.
Methods: In this genetic association case-control study, cannabinoid receptor polymorphisms CNR1 rs12720071 and CNR2 rs2229579 were tested for association with neurocognitive perfor...
Both cannabinoid agonists inhibited the proliferation and expression of EGFR in lung cancer cells, and CBD potentiated the effect of THC. THC and CBD inhibited the proliferation and ...
Microglia from CB2R−/− mice show enhanced lipofuscin accumulation in comparison to WT mice, which resulted in an interaction effect. Expression of arg1 (D) did not differ between age...
Nod-like receptor (NLR) family pyrin domain containing 3 (NLRP3) has been regarded as an important initiator or promoter in multiple inflammatory diseases. CB1 expression was increas...
We and others demonstrated that renal CB1R expression was increased in diabetic nephropathy, both in humans (12, 45) and rodents (14, 15, 17, 18). CB1R Activation Promotes Non-Metabo...
This molecule was found to be active against some cancer cell lines, especially M14 melanoma. To investigate whether the position at which the rings are attached to each other is imp...
During AD, the endocannabinoid system undergoes some changes, where the progress of the disease may be related to the CB1 levels, in addition to the alteration of the CB2 expression,...
Cannabinoids and Motivated Action Under a Variety of Reinforcement Contingencies Response Reinforcement and Schedule-Controlled Behavior While many different behavioral approaches ...
Cell Rep. 2018, 22, 1509–1521. Cell 2016, 167, 829–842.e13. Cell Rep. 2019, 28, 3011–3021.e4. Cell. Cells 2019, 8, 1293.
Several studies have observed that the activation of CB2 receptors decrease neuroinflammation in animal models of AD (Uddin et al., 2020). However, since PF3845 not only induced an i...
Besides the studies regarding the functions of the ECS in primary olfactory structures, it is important to take into account that CB1 receptors are present and modulate associated ol...
Cells 2017, 171, 1678–1691.e1613. Cells 2019, 8, 1013. Cancer Cell 2019, 35, 17–32.e16. Cell 2005, 16, 2091–2105. Cell.
In June 2015, the patient progressed to severe dementia stage and behavioral symptoms (agitation, disruptive behavior, anxiety) worsened again. In the course of treatment with dronab...